CAMBRIDGE, Mass.--(BUSINESS WIRE)--Montai Therapeutics, a company pioneering at the intersection of AI, diverse human chemistry and validated biology to discover breakthrough small molecules for chronic disease, is expanding its network of renowned scientific and technical advisors with the appointment of Larry Hamann to its Board of Directors and the launch of the company’s Scientific Advisory Board (SAB)..

马萨诸塞州剑桥市。-（商业新闻短讯）--Montai Therapeutics是一家集人工智能、多种人类化学和经过验证的生物学为一体的公司，致力于发现突破性的慢性病小分子，该公司正在扩大其著名科学和技术顾问网络，任命拉里·哈曼为董事会成员，并成立了该公司的科学顾问委员会（SAB）。。

“Larry brings a distinguished legacy of drug discovery and chemistry innovation to Montai to help us unlock the full potential of our richly diverse Anthromolecule™ chemistry and deliver breakthrough small molecules for pathways in chronic disease that have been viewed as ‘undruggable’ by the rest of the drug industry,” said Margo Georgiadis, Co-founder and CEO of Montai and CEO-Partner, Flagship Pioneering.

“拉里为蒙泰带来了杰出的药物发现和化学创新遗产，帮助我们释放我们丰富多样的Anthromolecule™化学的全部潜力，并为慢性病的途径提供突破性的小分子，这些途径被其他制药行业视为“不可治疗的”，蒙泰联合创始人兼首席执行官兼首席执行官合伙人，旗舰先锋马戈·乔治亚迪斯（Margo Georgiadis）说。

“Within our Boards, we’ve assembled thought leaders in AI, chemistry, biology, drug development and bio platform innovation to address the urgent need for more accessible, safer medicines to treat chronic inflammatory and autoimmune diseases. We are deeply grateful for their commitment to our mission.”.

“在我们的董事会中，我们聚集了人工智能、化学、生物学、药物开发和生物平台创新方面的思想领袖，以解决对更容易获得、更安全的药物治疗慢性炎症和自身免疫性疾病的迫切需求。我们非常感谢他们对我们使命的承诺。”。

Dr. Hamann is currently Co-founder and CEO of Interdict Bio. Previously, he was Global Head, Drug Discovery Sciences at Takeda Pharmaceuticals, and prior to that, Corporate Vice President and Global Head, Small Molecule Drug Discovery at Celgene. Prior to Celgene, Larry held positions of increasing responsibility at Novartis, Bristol-Myers Squibb, and Ligand Pharmaceuticals.

哈曼博士目前是Interdict Bio的联合创始人兼首席执行官。此前，他曾担任武田制药公司药物发现科学全球负责人，在此之前，他曾担任Celgene公司副总裁兼小分子药物发现全球负责人。在加入Celgene之前，Larry在诺华、百时美施贵宝和Ligand Pharmaceuticals担任越来越重要的职位。

In more than 30 years of drug discovery, he has led teams responsible for more than 22 clinical stage compounds, including several first-in-class therapeutics, and two launched drugs. Further, he is co-inventor on more than 70 patents and co-author of more than 90 scientific publications. Dr. Hamann was awarded the American Chemical Society (ACS) Division of Medicinal Chemistry Award in 2022.

在30多年的药物发现中，他领导的团队负责22种以上的临床阶段化合物，包括几种一流的治疗药物和两种上市药物。此外，他还是70多项专利的共同发明人，并与他人合著了90多种科学出版物。哈曼博士于2022年获得美国化学学会（ACS）药物化学奖。

He earned a PhD in Organic Chemistry from the University of Michigan..

他获得了密歇根大学有机化学博士学位。。

“The opportunity to explore diverse, untapped human chemistry is what attracted me to Montai because this work breaks away from the typical chemical space that has been targeted for drug development. What’s particularly exciting is the use of AI to systematically aggregate and generate insights from this library, which will make it possible to find transformational solutions for even the most complex biological pathways,” said Dr.

“探索多样的，未开发的人类化学的机会吸引了我来到蒙泰，因为这项工作打破了药物开发所针对的典型化学空间。特别令人兴奋的是，使用人工智能系统地汇总和产生来自这个库的见解，这将使我们有可能为最复杂的生物途径找到变革性的解决方案，”博士说。

Hamann. “The depth of this rich chemical equity, with a wide range of available vectors for further elaboration to better engage target binding pockets with precision and selectivity, is essential to address challenging targets like transcription factors, or to introduce solutions that could replace complex biologics.”.

哈曼。“这种丰富的化学公平性的深度，以及广泛的可用载体，可用于进一步阐述，以更好地精确和选择性地参与目标结合口袋，对于解决转录因子等具有挑战性的目标，或引入可以替代复杂生物制剂的解决方案至关重要。”。

Montai’s newly formalized SAB brings together recognized industry and academic leaders to inform and accelerate the company’s strategy to define a new paradigm for predictable small molecule drug discovery to address important unmet patient needs across chronic disease. Integrating untapped diverse chemistry and AI into the discovery equation provides insight generation and optionality far beyond conventional processes to solve challenges that have, until now, eluded small molecule drug developers.

Montai新正式成立的SAB汇集了公认的行业和学术领袖，为公司的战略提供信息和加速，以定义可预测的小分子药物发现的新范例，以解决慢性病患者未满足的重要需求。将未开发的多种化学和人工智能整合到发现方程中，提供了远远超出常规过程的洞察力生成和可选性，以解决迄今为止小分子药物开发人员所面临的挑战。

The SAB integrates world-class experts from immunology, chemistry, systems biology and AI to fine-tune this strategy and increase the probability of success..

SAB整合了来自免疫学、化学、系统生物学和人工智能的世界级专家，以微调该策略并提高成功概率。。

“At this intersection of chemistry, biology and AI, I see an exciting opportunity for Montai to introduce a radically different approach to drug discovery that could solve for some of the most challenging targets in immunological diseases,” said Keith James, Ph.D., SAB member and former President, Ferring Research Institute, and Senior Vice-President and Head of Drug Discovery at Insitro and Pfizer.

“在化学、生物学和人工智能的这个交叉点上，我看到了一个令人兴奋的机会，蒙泰可以引入一种完全不同的药物发现方法，可以解决免疫疾病中一些最具挑战性的目标，”南非国家统计局成员、费林研究所前总裁、Insitro和辉瑞公司高级副总裁兼药物发现负责人基思·詹姆斯（KeithJames）博士说。

“Leading-edge AI is uniquely equipped to systematically assess diverse chemistry to interrogate under-explored regions of drug-like chemical space and identify candidates that can best target these validated pathways. Furthermore, Montai’s ability to generate multiple, diverse candidates, each with high potential for success, offers drug discoverers an extremely attractive set of design options – a huge enabler for the drug discovery model.”.

“领先的人工智能具有独特的能力，可以系统地评估各种化学物质，以审问药物样化学空间中探索不足的区域，并确定最能针对这些经过验证的途径的候选药物。此外，蒙太伊能够产生多种多样的候选药物，每种候选药物都具有很高的成功潜力，为药物发现者提供了一套极具吸引力的设计选择，这是药物发现模型的巨大推动者。”。

Montai formally welcomes the following distinguished thought leaders to its SAB:

Montai正式欢迎以下杰出的思想领袖加入SAB：

Connor Coley, Ph.D.: Assistant Professor of Chemical Engineering & Electrical Engineering and Computer Science at Massachusetts Institute of Technology; recognized innovator at the interface of chemistry, data science, machine learning, and robotics with an emphasis on how AI, data and automation can streamline discovery and chemical synthesis.

康纳·科利博士：麻省理工学院化学工程、电气工程和计算机科学助理教授；化学、数据科学、机器学习和机器人学领域公认的创新者，重点关注人工智能、数据和自动化如何简化发现和化学合成。

Jim Collins, Ph.D.: Termeer Professor of Medical Engineering & Science, MIT; Core Founding Faculty Member, Wyss Institute, Harvard; Institute Member, Broad Institute of MIT and Harvard; a pioneer of the field of synthetic biology, focused on using synthetic biology to create next-generation diagnostics and therapeutics with a focus on AI for antibiotics.

吉姆·柯林斯博士：麻省理工学院医学工程与科学特米尔教授；哈佛大学Wyss研究所核心创始教员；麻省理工学院和哈佛大学布罗德研究所成员；合成生物学领域的先驱，专注于使用合成生物学创建下一代诊断和治疗方法，重点是抗生素的人工智能。

Keith James, Ph.D.: Former President, Ferring Research Institute, and Senior Vice-President and Head of Drug Discovery at Insitro and Pfizer; extensive industry experience applying machine learning to the discovery of new medicines

基思·詹姆斯（KeithJames），博士：费林研究所（Ferring Research Institute）前院长，Insitro和辉瑞（Pfizer）高级副总裁兼药物发现主管；将机器学习应用于新药发现的广泛行业经验

Luke O’Neill, Ph.D.: Professor and Chair of Biochemistry and Immunology, Trinity College; renowned immunologist focused on inflammation and innate immunity, molecular analysis of inflammatory diseases and immunometabolism

卢克·奥尼尔博士：三一学院生物化学与免疫学教授兼主席；著名的免疫学家专注于炎症和先天免疫，炎症性疾病的分子分析和免疫代谢

Iain McInnes, Ph.D., M.B.Ch.B: Vice Principal and Head of College of Medical, Veterinary and Life Sciences, Muirhead Chair of Medicine, Versus Arthritis Professor of Rheumatology, University of Glasgow; built an internationally recognized research program on the cellular and molecular pathways driving inflammatory joint disease which enabled key therapeutic innovations.

Iain McInnes博士，M.B.Ch.B：副校长兼医学，兽医和生命科学学院院长，医学Muirhead主席，格拉斯哥大学风湿病与关节炎教授；建立了一个国际公认的关于驱动炎症性关节疾病的细胞和分子途径的研究计划，从而实现了关键的治疗创新。

Paul Ridker, M.D.: Eugene Braunwald Professor of Medicine, Harvard University and Brigham and Women's Hospital; Director of the Center for Cardiovascular Disease Prevention; renowned expert in inflammation and cardiovascular disease; pioneered clinical research proving inflammation hypothesis in atherosclerosis, coronary artery disease, and more.

Paul Ridker，医学博士：哈佛大学和布莱根妇女医院的尤金·布劳沃尔德医学教授；心血管疾病预防中心主任；炎症和心血管疾病领域的著名专家；开创性的临床研究证明了动脉粥样硬化，冠状动脉疾病等炎症假说。

Peter Sorger, Ph.D.: Otto Krayer Professor of Systems Pharmacology, Head of the Harvard Program in Therapeutic Sciences (HiTS), Harvard Medical School; Cofounder, Merrimack Pharmaceuticals; renowned expertise in systems biology, AI, and network knowledge aggregation

Peter Sorger博士：Otto Krayer系统药理学教授，哈佛医学院哈佛治疗科学项目（HiTS）负责人；Merrimack Pharmaceuticals联合创始人；在系统生物学、人工智能和网络知识聚合方面享有盛誉

About Montai Therapeutics

关于Montai Therapeutics

Montai is pioneering with AI to predictably discover breakthrough small molecule medicines, precision-matching untapped human chemistry to validated biological pathways to address unmet needs in chronic disease. Montai’s CONECTA platform leverages AI to build deep network understanding of the connections between human biology and highly diverse Anthromolecule™ chemistry – curated bioactive molecules with a long history of human consumption in foods, supplements, and herbal medicines.

Montai是人工智能的先驱，可以预见地发现突破性的小分子药物，将未开发的人类化学与经过验证的生物途径精确匹配，以解决慢性病未满足的需求。Montai的CONECTA平台利用人工智能建立对人类生物学和高度多样化的Anthromolecule™化学之间联系的深入网络理解，这些化学是人类在食品、补充剂和草药中消费历史悠久的生物活性分子。

From this precision-matched human co-evolved chemistry, Montai’s generative AI systems unlock access to and rapid optimization of the widest range of high-potential drug candidates, providing unprecedented optionality and predictability in drug development. With an initial focus on inflammatory and autoimmune diseases, Montai is developing a pipeline of accessible, pill-based solutions as biologic replacements and for hard-to-drug targets such as transcription factors.

从这种精确匹配的人类共同进化化学中，Montai的生成性人工智能系统解锁了对最广泛的高潜力候选药物的访问和快速优化，为药物开发提供了前所未有的可选性和可预测性。Montai最初专注于炎症和自身免疫性疾病，目前正在开发一系列可获得的基于药丸的解决方案，作为生物替代品和转录因子等难以药物靶点。

Montai was founded in Flagship Labs in 2019. For more information, please visit www.montai.com or follow us on Twitter and LinkedIn..

Montai于2019年在旗舰实验室成立。有关更多信息，请访问www.montai.com或在Twitter和LinkedIn上关注我们。。